First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors.

ABSTRACT: Src homology-2 domain-containing phosphatase 2 promotes rat sarcoma viral oncogene homolog-MAPK signaling and tumorigenesis and is a promising therapeutic target for multiple solid tumors. Migoprotafib is a potent and highly selective Src homology-2 domain-containing phosphatase 2 inhibitor designed for the treatment of rat sarcoma viral oncogene homolog-MAPK-driven cancers, particularly in combination with other targeted agents. Here, we report first-in-human study results of single-agent migoprotafib in patients with advanced solid tumor. We conducted a phase Ia, open-label, multi-center, dose-escalation and expansion study in adult patients with locally advanced or metastatic solid tumors. The key objectives were to evaluate safety, pharmacokinetics (PK), pharmacodynamics (peripheral bl

SUBMITTER: Johnson ML 

PROVIDER: S-EPMC11876956 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature